Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Retained Earnings (2018 - 2025)

Summit Therapeutics' Retained Earnings history spans 8 years, with the latest figure at -$2.1 billion for Q3 2025.

  • For Q3 2025, Retained Earnings fell 79.91% year-over-year to -$2.1 billion; the TTM value through Sep 2025 reached -$2.1 billion, down 79.91%, while the annual FY2024 figure was -$2.3 million, 99.77% up from the prior year.
  • Retained Earnings reached -$2.1 billion in Q3 2025 per SMMT's latest filing, down from -$1.8 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$1.9 million in Q4 2022 to a low of -$2.1 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$562.3 million, with a median of -$299.5 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: skyrocketed 99.77% in 2024, then tumbled 73657.26% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$299.5 million in 2021, then surged by 99.37% to -$1.9 million in 2022, then crashed by 52370.05% to -$993.3 million in 2023, then surged by 99.77% to -$2.3 million in 2024, then tumbled by 90709.06% to -$2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Retained Earnings are -$2.1 billion (Q3 2025), -$1.8 billion (Q2 2025), and -$2.6 million (Q1 2025).